Log in

6996 Antengene Corporation Limited HKEX · China

Antengene Corporation (6996) news

Antengene Corporation Limited is a public biotech or pharmaceutical company listed on HKEX under the ticker 6996, recorded under China. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest Antengene Corporation news

We have not published a story on Antengene Corporation yet. When there is news, it will appear here.

Questions about Antengene Corporation

What is the ticker symbol of Antengene Corporation?

Antengene Corporation Limited trades under the ticker 6996 on HKEX.

Where is Antengene Corporation listed?

Antengene Corporation Limited is listed on HKEX.

Which country or territory is Antengene Corporation listed under?

Our directory records Antengene Corporation Limited under China.

What does Antengene Corporation do?

Our directory classifies Antengene Corporation Limited as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.

What is the ISIN of Antengene Corporation?

The ISIN recorded for Antengene Corporation Limited is KYG039571008.

Does aibio.space cover Antengene Corporation?

aibio.space lists Antengene Corporation Limited among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to Antengene Corporation?

Companies in our directory listed in the same country and business area as Antengene Corporation: CASI Pharmaceuticals, Xiangxue Pharmaceutical Co., Hainan Huluwa Pharmaceutical Group Co., Hangzhou Bio-Sincerity Pharma-Tech Co., Bide Pharmatech Co., Wanbangde Pharmaceutical Holding Group Co..

Investor discussion: Antengene Corporation

Members talk about Antengene Corporation (6996). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Antengene Corporation, newest first. Each line links the filing it comes from.

  1. Financings

    Share or debt issue: (1) PROPOSALS FOR GENERAL MANDATES TO ISSUE AND RESELL SHARES AND TO REPURCHASE SHARES; (2) RE-ELECTION OF DIRECTORS; (3) RE-APPOINTMENT OF THE AUDITOR; (4) PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION AND ADOPTION OF THE AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION; AND (5) NOTICE OF ANNUAL GENERAL MEETING. Source

  2. Financings

    Share or debt issue: (1) PROPOSALS FOR GENERAL MANDATES TO ISSUE AND RESELL SHARES AND TO REPURCHASE SHARES; (2) RE-ELECTION OF DIRECTORS; AND (3) NOTICE OF ANNUAL GENERAL MEETING. Source

Press releases

Headlines of Antengene Corporation's own announcements, newest first. Each opens the full release on the newswire that carried it.

  1. HKEXnews

    GRANT OF RSUs UNDER THE 2022 RSU SCHEME

  2. HKEXnews

    VOLUNTARY ANNOUNCEMENT HREC APPROVAL IN AUSTRALIA FOR PHASE I ATTRACT STUDY OF ATG-201 IN B CELL-RELATED AUTOIMMUNE DISEASES

  3. HKEXnews

    ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED JUNE 30, 2026

  4. HKEXnews

    (1) RESIGNATION OF EXECUTIVE DIRECTOR AND CHIEF FINANCIAL OFFICER (2) APPOINTMENT OF EXECUTIVE DIRECTOR (3) APPOINTMENT OF CHIEF BUSINESS OFFICER (4) CHANGE OF AUTHORIZED REPRESENTATIVE AND PROCESS AGENT

  5. HKEXnews

    POSITIVE PROFIT ALERT

  6. HKEXnews

    VOLUNTARY ANNOUNCEMENT RECEIPT OF USD60 MILLION UPFRONT PAYMENT FROM UCB FOR ATG-201

  7. HKEXnews

    VOLUNTARY ANNOUNCEMENT INTENTION TO CONDUCT ON-MARKET SHARE REPURCHASE

  8. HKEXnews

    VOLUNTARY ANNOUNCEMENT EXCLUSIVE LICENSE AGREEMENT WITH MPM BIOIMPACT ESTABLISHED K2 THERAPEUTICS FOR ATG-106 AND OPTION FOR UNDISCLOSED BISPECIFIC TCE

  9. HKEXnews

    CHANGE OF JOINT COMPANY SECRETARIES AND WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES

  10. HKEXnews

    NINTH AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION

  11. HKEXnews

    POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 10, 2026

  12. HKEXnews

    VOLUNTARY ANNOUNCEMENT IND APPROVAL FOR ATG-201 (CD19 x CD3 TCE) IN AUTOIMMUNE DISEASE IN CHINA

  13. HKEXnews

    VOLUNTARY ANNOUNCEMENT CHINA IND APPROVAL FOR PIVOTAL PHASE III CLINCH-3 STUDY OF ATG-022 IN CLDN18.2+ ADVANCED GASTRIC/GEJ CANCER

  14. HKEXnews

    VOLUNTARY ANNOUNCEMENT APPOINTMENT OF CHIEF SCIENTIFIC OFFICER

  15. HKEXnews

    NOTICE OF THE ANNUAL GENERAL MEETING

  16. HKEXnews

    (1) PROPOSALS FOR GENERAL MANDATES TO ISSUE AND RESELL SHARES AND TO REPURCHASE SHARES; (2) RE-ELECTION OF DIRECTORS; (3) RE-APPOINTMENT OF THE AUDITOR; (4) PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION AND ADOPTION OF THE AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION; AND (5) NOTICE OF ANNUAL GENERAL MEETING

  17. HKEXnews

    PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION AND ADOPTION OF THE NINTH AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION

  18. HKEXnews

    GRANT OF SHARE OPTIONS AND RSUS

  19. HKEXnews

    VOLUNTARY ANNOUNCEMENT INCREASE IN SHAREHOLDING BY FOUNDER, CEO, CHAIRMAN AND OTHER MANAGEMENT

  20. HKEXnews

    ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2025

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open HKEX:6996 on TradingView.

Listing details

Antengene Corporation Limited is a public biotech or pharmaceutical company listed on HKEX under the ticker 6996, recorded under China. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
Antengene Corporation Limited
Ticker
6996
Listing
HKEX
Country or territory
China
Business scope
Pharmaceuticals: Major
ISIN
KYG039571008
Last quote in directory
2026-10-22
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.